Gargi Bagchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gargi Bagchi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Gunjan Dagar
Amity Univ, Amity Inst Biotechnol, Gurgaon 122413, India
4 shared publicationsVersha Dahiya
3 shared publicationsJulie Pratibha Singh
Affiliation Amity Institute of Biotechnology (AIB), Amity University Haryana, Manesar, Gurugram, India
2 shared publicationsManisha Dagar
Affiliation Amity Institute of Biotechnology (AIB), Amity University Haryana, Manesar, Gurugram, India
2 shared publicationsRakesh Kumar Tyagi
2 shared publicationsRavi Datta Sharma
2 shared publications
Latest Publications
- Open Access
- 6 December 2024
- Published by Informatics Publishing Limited in Journal of Endocrinology and Reproduction
- p. 79-87
Impact of High-Volume Chemicals on Androgen Signalling and Male Reproductive Health
Endocrine-disrupting chemicals, or EDCs, are the chemicals in the environment that can alter hormonal functions in humans and animals. Many industrial chemicals that act as EDCs are used and produced in large quantities worldwide. Because of their large-scale production, they are known as ‘High volume chemicals’ or HVCs. Humans and animals are exposed to these chemicals by day-to-day use of different products or through contaminated food or water. These HVCs greatly impact the hormone system of exposed living beings and their physiology. Many of these high-volume EDCs specifically interfere with male hormone (androgen) signalling by influencing biosynthesis, metabolism, and function of the Androgen Receptor (AR), resulting in a disruption of typical male developmental programming. As androgen is critical for male sexual differentiation, males are extremely susceptible to these androgen disruptors. Animal exposure studies demonstrate that these androgen disruptors lead to a decrease in sperm count, infertility, testicular dysgenesis, and prostate cancer, which is prevalent in many parts of the world today. Routinely used HVCs that can act as androgen-disruptors include Bisphenol (BPA), Phthalates, Dichlorodiphenyltrichloroethane (DDT), Glyphosate and Methoxy, Methoxyacetic Acid (MAA), among others. These chemicals disrupt androgen signalling by different mechanisms and result in the disruption of normal male physiological processes. This review highlights the toxicities and molecular mechanisms of hormone disruption induced by these routinely used high-volume chemicals that disrupt androgen signalling.
- 6 December 2024
- Published by Informatics Publishing Limited in Journal of Endocrinology and Reproduction
- p. 79-87
Open AccessImpact of High-Volume Chemicals on Androgen Signalling and Male Reproductive Health
Endocrine-disrupting chemicals, or EDCs, are the chemicals in the environment that can alter hormonal functions in humans and animals. Many industrial chemicals that act as EDCs are used and produced in large quantities worldwide. Because of their large-scale production, they are known as ‘High volume chemicals’ or HVCs. Humans and animals are exposed to these chemicals by day-to-day use of different products or through contaminated food or water. These HVCs greatly impact the hormone system of exposed living beings and their physiology. Many of these high-volume EDCs specifically interfere with male hormone (androgen) signalling by influencing biosynthesis, metabolism, and function of the Androgen Receptor (AR), resulting in a disruption of typical male developmental programming. As androgen is critical for male sexual differentiation, males are extremely susceptible to these androgen disruptors. Animal exposure studies demonstrate that these androgen disruptors lead to a decrease in sperm count, infertility, testicular dysgenesis, and prostate cancer, which is prevalent in many parts of the world today. Routinely used HVCs that can act as androgen-disruptors include Bisphenol (BPA), Phthalates, Dichlorodiphenyltrichloroethane (DDT), Glyphosate and Methoxy, Methoxyacetic Acid (MAA), among others. These chemicals disrupt androgen signalling by different mechanisms and result in the disruption of normal male physiological processes. This review highlights the toxicities and molecular mechanisms of hormone disruption induced by these routinely used high-volume chemicals that disrupt androgen signalling.
- 14 May 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (10) , 2444-2456
Prostate cancer biomarkers: from early diagnosis to precision treatment
Prostate cancer (PCa) is the second most prevalent cancer in men. In 2020, approximately 1,414,259 new cases were reported that accounted for 3,75,324 deaths (Sung et al. in CA 71:209–249, 2021). PCa is often asymptomatic at early stages; hence, routine screening and monitoring based on reliable biomarkers is crucial for early detection and assessment of cancer progression. Early diagnosis of disease is key step in reducing PCa-induced mortality. Biomarkers such as PSA have played vital role in reducing recent PCa deaths. Recent research has identified many other biomarkers and also refined PSA-based tests for non-invasive diagnosis of PCa in patients. Despite progress in screening methods, an important issue that influences treatment is heterogeneity of the cancer in different individuals, necessitating personalized treatment. Currently, focus is to identify biomarkers that can accurately diagnose PCa at early stage, indicate the stage of the disease, metastatic nature and chances of survival based on individual patient profile (Fig. 1). Graphical abstract
- 14 May 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (10) , 2444-2456
Prostate cancer biomarkers: from early diagnosis to precision treatment
Prostate cancer (PCa) is the second most prevalent cancer in men. In 2020, approximately 1,414,259 new cases were reported that accounted for 3,75,324 deaths (Sung et al. in CA 71:209–249, 2021). PCa is often asymptomatic at early stages; hence, routine screening and monitoring based on reliable biomarkers is crucial for early detection and assessment of cancer progression. Early diagnosis of disease is key step in reducing PCa-induced mortality. Biomarkers such as PSA have played vital role in reducing recent PCa deaths. Recent research has identified many other biomarkers and also refined PSA-based tests for non-invasive diagnosis of PCa in patients. Despite progress in screening methods, an important issue that influences treatment is heterogeneity of the cancer in different individuals, necessitating personalized treatment. Currently, focus is to identify biomarkers that can accurately diagnose PCa at early stage, indicate the stage of the disease, metastatic nature and chances of survival based on individual patient profile (Fig. 1). Graphical abstract
- 11 September 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1869 (12) , 119357
Non-canonical androgen signaling pathways and implications in prostate cancer
- 11 September 2022
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1869 (12) , 119357
Non-canonical androgen signaling pathways and implications in prostate cancer
- Open Access
- 3 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0226056
Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells
The androgen receptor (AR) is activated in patients with castration resistant prostate cancer (CRPC) despite low circulating levels of androgen, suggesting that intracellular signaling pathways and non-androgenic factors may contribute to AR activation. Many G-protein coupled receptors (GPCR) and their ligands are also activated in these cells indicating that they may play a role in development of Prostate Cancer (PCa) and CRPC. Although a cross talk has been suggested between the two pathways, yet, the identity of GPCRs which may play a role in androgen signaling, is not established yet. By using blast analysis of 826 GPCRs, we identified a GPCR, GPCR 205, which exhibited maximum similarity with the ligand binding domain of the AR. We demonstrate that adhesion GPCR 205, also known as GPR56, can be activated by androgens to stimulate the Rho signaling pathway, a pathway that plays an important role in prostate tumor cell metastasis. Testosterone stimulation of GPR56 also activates the cAMP/ Protein kinase A (PKA) pathway, that is necessary for AR signaling. Knocking down the expression of GPR56 using siRNA, disrupts nuclear translocation of AR and transcription of prototypic AR target genes such as PSA. GPR56 expression is higher in all twenty-five prostate tumor patient’s samples tested and cells expressing GPR56 exhibit increased proliferation. These findings provide new insights about androgen signaling and identify GPR56 as a possible therapeutic target in advanced prostate cancer patients.
- 3 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0226056
Open AccessActivation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells
The androgen receptor (AR) is activated in patients with castration resistant prostate cancer (CRPC) despite low circulating levels of androgen, suggesting that intracellular signaling pathways and non-androgenic factors may contribute to AR activation. Many G-protein coupled receptors (GPCR) and their ligands are also activated in these cells indicating that they may play a role in development of Prostate Cancer (PCa) and CRPC. Although a cross talk has been suggested between the two pathways, yet, the identity of GPCRs which may play a role in androgen signaling, is not established yet. By using blast analysis of 826 GPCRs, we identified a GPCR, GPCR 205, which exhibited maximum similarity with the ligand binding domain of the AR. We demonstrate that adhesion GPCR 205, also known as GPR56, can be activated by androgens to stimulate the Rho signaling pathway, a pathway that plays an important role in prostate tumor cell metastasis. Testosterone stimulation of GPR56 also activates the cAMP/ Protein kinase A (PKA) pathway, that is necessary for AR signaling. Knocking down the expression of GPR56 using siRNA, disrupts nuclear translocation of AR and transcription of prototypic AR target genes such as PSA. GPR56 expression is higher in all twenty-five prostate tumor patient’s samples tested and cells expressing GPR56 exhibit increased proliferation. These findings provide new insights about androgen signaling and identify GPR56 as a possible therapeutic target in advanced prostate cancer patients.
- Open Access
- 4 February 2020
- Published by Springer Nature
- p. 411-429
Nanoparticles as Potential Endocrine Disruptive Chemicals
- 4 February 2020
- Published by Springer Nature
- p. 411-429
Open AccessNanoparticles as Potential Endocrine Disruptive Chemicals
- Open Access
Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells
The androgen receptor (AR) is activated in patients with castration resistant prostate cancer (CRPC) despite low circulating levels of androgen, suggesting that intracellular signaling pathways and non-androgenic factors may contribute to AR activation. Many G-protein coupled receptors (GPCR) and their ligands are also activated in these cells indicating a role for these in CRPC. Although a cross talk has been suggested between the two pathways, yet, the identity of GPCRs which may play a role in androgen signaling, is not established yet. We demonstrate that adhesion GPCR 205, also known as GPR56, can be activated by androgens to stimulate the Rho signaling pathway, a pathway that plays an important role in prostate tumor cell metastasis. Testosterone stimulation of GPR56 also activates the cAMP/ Protein kinase A (PKA) pathway, that is necessary for AR signaling. Knocking down the expression of GPR56 using siRNA, disrupts nuclear translocation of AR and transcription of prototypic AR target genes such as PSA. GPR56 expression is higher in all prostate tumor samples tested and cells expressing GPR56 exhibit increased proliferation. These findings provide new insights about androgen signaling and identify GPR56 as a possible therapeutic target in advanced prostate cancer patients.
Open AccessActivation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells
The androgen receptor (AR) is activated in patients with castration resistant prostate cancer (CRPC) despite low circulating levels of androgen, suggesting that intracellular signaling pathways and non-androgenic factors may contribute to AR activation. Many G-protein coupled receptors (GPCR) and their ligands are also activated in these cells indicating a role for these in CRPC. Although a cross talk has been suggested between the two pathways, yet, the identity of GPCRs which may play a role in androgen signaling, is not established yet. We demonstrate that adhesion GPCR 205, also known as GPR56, can be activated by androgens to stimulate the Rho signaling pathway, a pathway that plays an important role in prostate tumor cell metastasis. Testosterone stimulation of GPR56 also activates the cAMP/ Protein kinase A (PKA) pathway, that is necessary for AR signaling. Knocking down the expression of GPR56 using siRNA, disrupts nuclear translocation of AR and transcription of prototypic AR target genes such as PSA. GPR56 expression is higher in all prostate tumor samples tested and cells expressing GPR56 exhibit increased proliferation. These findings provide new insights about androgen signaling and identify GPR56 as a possible therapeutic target in advanced prostate cancer patients.
- Open Access
- 1 May 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (22) , 8699-8710
Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor
- 1 May 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (22) , 8699-8710
Open AccessPhosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor
- Open Access
- 9 November 2014
- Published by Hindawi Limited in Journal of Toxicology
- Vol. 2014, 1-7
In VitroReporter Assays for Screening of Chemicals That Disrupt Androgen Signaling
Endocrine disruptive chemicals (EDCs) modulate hormone signaling and cause developmental and reproductive anomalies. Today, there is a global concern regarding endocrine disruption effects, particularly those mediated by the androgen receptor (AR). Androgen or male hormones are critical for the development and maintenance of male characteristics and numerous EDCs exist in the environment with the potential to disrupt androgen action. The threat is more during critical developmental windows when there is increased sensitivity to these compounds. Timely screening and detection of the EDCs is essential to minimize deleterious effects produced by these toxic chemicals. As a first line of screening,in vitrotranscription assays are very useful due to their speed, convenience, and cost effectiveness. In this paper, recentin vitroreporter assays for detecting androgenic or antiandrogenic activity of EDCs have been reviewed. Two important cell systems used for this purpose, namely, the mammalian or yeast cell systems, have been discussed. Use of reporter genes such as bacterial luciferase (lux) and green fluorescent protein (gfp) has significantly improved speed and sensitivity of detection. Also, many of the current reporter assay systems can be used in a high throughput format allowing speedy evaluation of multiple potential EDCs at a lower price.
- 9 November 2014
- Published by Hindawi Limited in Journal of Toxicology
- Vol. 2014, 1-7
Open AccessIn VitroReporter Assays for Screening of Chemicals That Disrupt Androgen Signaling
Endocrine disruptive chemicals (EDCs) modulate hormone signaling and cause developmental and reproductive anomalies. Today, there is a global concern regarding endocrine disruption effects, particularly those mediated by the androgen receptor (AR). Androgen or male hormones are critical for the development and maintenance of male characteristics and numerous EDCs exist in the environment with the potential to disrupt androgen action. The threat is more during critical developmental windows when there is increased sensitivity to these compounds. Timely screening and detection of the EDCs is essential to minimize deleterious effects produced by these toxic chemicals. As a first line of screening,in vitrotranscription assays are very useful due to their speed, convenience, and cost effectiveness. In this paper, recentin vitroreporter assays for detecting androgenic or antiandrogenic activity of EDCs have been reviewed. Two important cell systems used for this purpose, namely, the mammalian or yeast cell systems, have been discussed. Use of reporter genes such as bacterial luciferase (lux) and green fluorescent protein (gfp) has significantly improved speed and sensitivity of detection. Also, many of the current reporter assay systems can be used in a high throughput format allowing speedy evaluation of multiple potential EDCs at a lower price.